U.S. Markets open in 3 hrs 28 mins

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
188.36+0.87 (+0.46%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close187.49
Open189.57
Bid185.75 x 1200
Ask193.14 x 1200
Day's Range185.64 - 189.17
52 Week Range185.64 - 306.08
Volume4,314,228
Avg. Volume1,914,582
Market Cap48.76B
Beta (5Y Monthly)0.68
PE Ratio (TTM)17.95
EPS (TTM)10.49
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est262.90
  • Cathie Wood Bought This Stock for a Bargain. Should You Follow?
    Motley Fool

    Cathie Wood Bought This Stock for a Bargain. Should You Follow?

    Star investor Cathie Wood is usually one to follow. In less than a year, the biotech company ended development of two candidates in one of its rare-disease programs. Now the question is, should you follow Wood's lead and consider shares of this biotech company?

  • Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS
    Zacks

    Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

    The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

  • Vertex in a Vortex, But Recent Failures Can Be Turned Around
    TipRanks

    Vertex in a Vortex, But Recent Failures Can Be Turned Around

    Sometimes a potential drug or treatment may seem like a failure, but can still be salvaged for researchers' use. That is the case with Vertex Pharmaceuticals Inc.'s (VRTX) VX-864 for Alpha-1 Antitrypsin Deficiency (AATD). In its June 10 update to investors, the company announced that it will not be moving the drug to late-stage development. (See VRTX stock analysis on TipRanks) Five-star analyst Hartaj Singh of Oppenheimer & Co. covered the stock in his report, optimistically stating that the fa